Analytical Data
-
Gene name
B7-H4
- Application
-
Alternative Names
B7 homolog 4 ;B7-H4B7h.5Immune costimulatory protein B7-H4Protein B7S1T-cell costimulatory molecule B7x
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q7Z7D3
-
Expression Region
26-258aa
-
Molecular Weight
29.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
B7-H4 is an immune checkpoint protein that belongs to the B7 family of molecules, which play a crucial role in regulating T-cell responses and maintaining immune tolerance. Research into B7-H4 has gained prominence due to its implications in cancer immunotherapy and autoimmunity. It is primarily expressed in various tumor tissues and has been associated with poor prognosis in several cancers, indicating its potential role as an inhibitory receptor that dampens anti-tumor immune responses. The identification of B7-H4 as a negative regulator of T-cell activation has prompted scientists to explore its recombinant protein form for therapeutic applications, including the development of monoclonal antibodies aimed at blocking its interaction with receptors on T-cells. This therapeutic strategy could enhance immune responses against tumors, making it a promising avenue in cancer treatment. Furthermore, understanding the structural and functional dynamics of B7-H4 through the study of its recombinant protein can provide valuable insights into its mechanism of action and its interactions with other immune modulators, ultimately leading to more effective strategies in harnessing the immune system for cancer therapy. The ongoing research also seeks to clarify its role in other diseases, particularly autoimmune disorders, where modulation of B7-H4 could restore immune balance. Overall, the investigation of B7-H4 recombinants not only holds potential for cancer immunotherapy but also enhances our understanding of immune regulation, paving the way for innovative treatments that could improve patient outcomes in a variety of diseases.
